Author: Zacks Small Cap Research

12345617640 / 1758 POSTS
By Brian Lantier, CFA NASDAQ:XPON When investors hear the words Lithium batteries, the obvious first thought is the electric vehicle (EV) market and rightly so, as explosive demand for EVs is expected to result in a 300-400% increase in the lithium b ...
By Thomas Kerr, CFA NASDAQ:HCDI READ THE FULL HCDI RESEARCH REPORT Harbor Custom Development (NASDAQ:HCDI) is a unique and diversified real estate development company involved in all aspects of the land development cycle including land acquisition, e ...
By Thomas Kerr, CFA NASDAQ:OEG Overview Orbital Energy Group, Inc. (NASDAQ:OEG) is a diversified infrastructure services company serving a variety of customers in the electric power, telecommunications, and renewable markets. The company’s operation ...
By Lisa Thompson OTC:VSQTF READ THE FULL VSQTF RESEARCH REPORT ➢ Victory Square Technologies (VST) (OTC:VSQTF) is an early-stage investor primarily in technology and health care companies in the US and Canada. It operates with a small staff that run ...
Bautz: By David Bautz, PhDNASDAQ:CFRX READ THE FULL CFRX RESEARCH REPORT Business Update DSMB Recommends DISRUPT Trial be Stopped for Futility On July 13, 2022, ContraFect Corp. (NASDAQ:CFRX) announced that the independent data safety monitoring boa ...
Bautz: By David Bautz, PhDOTC:APLIF | TSX:APLI.TO READ THE FULL APLIF RESEARCH REPORT Business Update New Late-Stage Program in Cutaneous Leishmaniasis On April 13, 2022, Appili Therapeutics Inc. (OTC:APLIF) (TSX:APLI.TO) announced the addition of A ...
By Beth Senko, CFA NASDAQ:SCTL READ THE FULL SCTL RESEARCH REPORT It’s an oft-repeated cycle in healthcare – businesses mature, needs change, and new sectors develop to fulfill those needs. Innovation is alive and well in the pharmaceutical space, an ...
By Thomas Kerr, CFA NASDAQ:HTCR Overview HeartCore Enterprises (NASDAQ:HTCR) is an established software development company based in Tokyo, Japan and operates in three core segments. These include 1) Content Management in which the core product is H ...
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Encouraging Data from Phase 1 Trial of EPI-7386 On June 27, 2022, ESSA Pharma, Inc. (NASDAQ:EPIX) provided an update on the company’s Phase 1 clinical trial of EPI-738 ...
By David Bautz, PhD OTC:ATBPF | TSX:ATE.TO READ THE FULL ATE.TO RESEARCH REPORT Business Update Phase 2 Post-Operative Pain Program to Initiate in Calendar 4Q22 Antibe Therapeutics, Inc. (OTC:ATBPF) (TSX:ATE.TO) is developing otenaproxesul as a solut ...
12345617640 / 1758 POSTS